

SUPPLEMENTARY INFORMATION

Supplementary Table 1

Number of Clinically Diagnosed Alzheimer's Dementia Cases and Controls for Each *APOE* Genotype

<i>APOE</i>	Neuropathologically Confirmed				Neuropathologically Unconfirmed				Combined			
	Cases	Controls	Total	%	Cases	Controls	Total	%	Cases	Controls	Total	%
2/2	5	19	24	0.5	16	70	86	0.4	21	89	110	0.4
2/3	113	147	260	5.2	450	1,610	2060	8.6	563	1,757	2320	8.0
3/3	1,273	638	1911	38.2	3,604	8,175	11779	49.4	4,877	8,813	13690	47.4
2/4	107	20	127	2.54	311	286	597	2.5	418	306	724	2.5
3/4	1,897	155	2052	41.0	4,690	2,998	7688	32.2	6,587	3,153	9740	33.7
4/4	623	10	633	12.6	288	1,359	1647	6.9	1,982	2,98	1982	6.9
TOTAL	4,018	989	5007	100	10,430	13,427	23857	100	14,448	14,416	28864	100

This table provides a summary of all cases with the clinical diagnosis of Alzheimer's dementia and all cognitively unimpaired controls with *APOE* genotypes in the ADGC database. Participants in the combined group consisted of neuropathologically confirmed autopsy and neuropathologically unconfirmed clinical subjects, excluding neuropathologically misclassified subjects. Since the ADGC used both clinical and neuropathological criteria to prioritize autopsy participants in the ADGC database, the table does not include a substantial number of clinically characterized but neuropathologically mischaracterized cases and controls.

Supplementary Table 2

Characteristics of Alzheimer's Dementia Cases and Controls in the Neuropathologically Confirmed and Unconfirmed Groups, including Ages at Dementia Onset or Last Clinical Exam, Ages at Death, and Sex

APOE	Neuropathologically Confirmed						Neuropathologically Unconfirmed			
	AD Cases			Controls			AD Cases		Controls	
	AAO*	AAD*	% Female	AAE*	AAD*	% Female	AAO*	% Female	AAE*	% Female
2/2	74.3 ± 0.8	82.3 ± 7.3	40	81.8 ± 8.6	85.2 ± 9.0	50	79.3 ± 8.2	0.63	77.4 ± 8.2	50
2/3	79.4 ± 9.0	86.3 ± 8.8	60	81.5 ± 9.8	83.5 ± 8.4	56	77.2 ± 8.4	0.54	77.3 ± 8.0	59
3/3	77.1 ± 8.9	83.9 ± 8.2	62	81.0 ± 8.4	82.1 ± 9.0	51	76.3 ± 7.8	0.59	76.6 ± 7.9	60
2/4	74.0 ± 6.1	83.3 ± 7.1	68	80.6 ± 9.6	82.5 ± 7.8	58	75.2 ± 6.9	0.63	75.4 ± 7.5	58
3/4	73.3 ± 7.2	81.9 ± 7.2	56	78.7 ± 8.9	80.9 ± 8.1	46	73.3 ± 6.7	0.61	74.4 ± 7.6	61
4/4	69.9 ± 6.1	79.0 ± 6.5	53	81.0 ± 5.9	79.0 ± 7.6	50	69.5 ± 5.9	0.55	72.2 ± 6.7	62
Total	74.2 ± 8.0	82.3 ± 7.7	58	80.7 ± 8.8	82.1 ± 8.7	51	74.1 ± 7.4	0.59	76.1 ± 7.9	60

* Mean±SD

The neuropathologically confirmed group contained participants available with clinical diagnosis, the APOE genotype, and an age variable (age at dementia onset, age at death, or age at last clinical evaluation). Affection status of cases and controls in the autopsied sample was defined by clinical diagnosis.

The neuropathologically unconfirmed clinical group includes clinically diagnosed but neuropathologically uncharacterized cases and controls.

AAO: Estimated age at dementia onset (when available) in the Alzheimer's dementia cases in years.

Only two APOE2 homozygotes with neuropathologically confirmed Alzheimer's dementia had an estimated AAO. AAO in the 65 combined APOE2/2 and 2/3 groups with neuropathologically confirmed Alzheimer's dementia was 79.3±9.0 years.

AAE: Age at last clinical evaluation (when available) in the combined cases and controls in years.

AAD: Age at death in the neuropathologically confirmed cases and controls in years.

Supplementary Table 3

Alzheimer's Dementia Odds Ratios for Each APOE genotype, Compared to APOE3/3, and for APOE2 and APOE4 Allelic Doses in the ADGC's Neuropathologically Confirmed and Unconfirmed Groups, after Adjustment for Age and Sex

<i>APOE</i>	Neuropathologically Confirmed			Neuropathologically Unconfirmed		
	OR	95% CI	P	OR	95% CI	P
Genotype						
2/2	0.16	0.06 - 0.43	3.0E-04	0.52	0.3 - 0.89	1.8E-02
2/3	0.40	0.31 - 0.53	3.6E-11	0.63	0.54 - 0.75	8.6E-08
2/4	2.47	1.51 - 4.04	3.4E-04	2.49	2.05 - 3.04	1.2E-19
3/4	5.71	4.71 - 6.92	8.2E-68	3.55	3.19 - 3.96	2.0E-115
4/4	26.93	14.39 - 50.38	2.1E-24	10.94	9.29 - 12.89	3.2E-180
Allelic Dose						
2	0.40	0.32 - 0.51	1.0E-13	0.64	0.58 - 0.72	1.7E-15
4	5.57	4.69 - 6.61	1.3E-81	3.42	3.24 - 3.60	<E-300

The "neuropathologically confirmed autopsy group" includes cases who met clinical and neuropathological criteria for Alzheimer's dementia and controls who were cognitively unimpaired and did not meet neuropathological criteria for AD at autopsy.

The "neuropathologically unconfirmed clinical group," includes cases who met clinical criteria for Alzheimer's dementia and cognitively unimpaired controls from the ADGC.

ORs associated with each APOE genotype were calculated using genotypic association tests compared to the APOE3/3 genotype as the reference in an additive genetic model after adjusting for age and sex.

ORs associated with APOE2 allelic dose in APOE4 non-carriers (APOE2/2<2/3<3/3) and APOE4 allelic dose in APOE2 non-carriers (APOE4/4>3/4>3/3) were generated using allelic association tests in an additive genetic model after adjusting for age and sex.

Supplementary Table 4

Alzheimer's Dementia Odds Ratios for Each APOE Genotype, Compared to APOE3/3, and for APOE2 and APOE4 Allelic Doses in the Combined Group, Before and After Adjustment for Age, Sex, and Autopsy Confirmed or Unconfirmed Sub-Group

APOE	Model 1 no adjustment			Model 2 age and sex adjustment			Model 3 age, sex and autopsy adjustment		
	OR	95% CI	P	OR	95% CI	P	OR	95% CI	P
Genotype									
2/2	0.43	0.26 - 0.7	7.4E-04	0.42	0.26 - 0.7	7.1E-04	0.35	0.20 - 0.61	2.0E-04
2/3	0.58	0.52 - 0.64	1.9E-25	0.58	0.52 - 0.64	3.1E-25	0.59	0.53 - 0.66	1.1E-21
2/4	2.47	2.12 - 2.87	2.7E-31	2.49	2.14 - 2.9	9.8E-32	2.49	2.13 - 2.92	3.8E-30
3/4	3.78	3.57 - 4	<E-300	3.78	3.57 - 4	<E-300	3.71	3.49 - 3.94	<E-300
4/4	12.02	10.58 - 13.66	<E-300	12.28	10.76 - 14.01	<E-300	11.39	9.96 - 13.02	3.1E-277
Allelic Dose									
2	0.59	0.53 - 0.65	9.1E-27	0.59	0.53 - 0.65	1.4E-26	0.59	0.53 - 0.65	3.1E-24
4	3.65	3.48 - 3.82	<E-300	3.64	3.47 - 3.83	<E-300	3.55	3.38 - 3.74	<E-300

The combined group included the 28,864 cases and controls from the neuropathologically confirmed and unconfirmed sub-groups.

Association tests in a logistic regression model were conducted using clinical diagnosis as an outcome without adjustment (Model 1), with age and sex as covariates (Model 2), and with age, sex, and autopsy status as covariates (Model 3).

ORs for each APOE genotype were calculated using genotypic association tests compared to the APOE3/3 genotype as the reference in an additive genetic model.

ORs associated with APOE2 allelic dose in APOE4 non-carriers (APOE2/2<2/3<3/3) and APOE4 allelic dose in APOE2 non-carriers (APOE4/4>3/4>3/3) were generated using allelic association tests in an additive genetic model.

Supplementary Table 5

Number of Neuropathologically Confirmed Alzheimer's Dementia Cases and Controls
With and Without Other Neuropathological Diagnoses for Each APOE Genotype

<i>APOE</i>	Congophilic Amyloid Angiopathy (CAA)		Lewy Body Disease (LBD)		Vascular Brain Injury (VBI)		Hippocampal Sclerosis (HS)	
	with	without	with	without	with	without	with	without
<i>2/2</i>	2	6	3	11	2	5	0	11
<i>2/3</i>	56	68	43	167	75	68	14	142
<i>3/3</i>	454	563	342	1054	482	583	104	1031
<i>2/4</i>	51	22	30	36	33	44	8	66
<i>3/4</i>	792	260	501	896	419	755	137	1058
<i>4/4</i>	292	71	156	252	112	232	27	317
TOTAL	1647	1090	1079	2428	1123	1687	290	2625

Supplementary Table 6

Odds Ratios for Other Assessed Neuropathological Diagnoses Compared to APOE3/3,
in the Neuropathologically Confirmed AD Case-Control Group

APOE	CAA			LBD			VBI			HS		
	OR	95% CI	P	OR	95% CI	P	OR	95% CI	P	OR	95% CI	P
Unadjusted												
2/2	0.41	0.08 - 2.06	2.8E-01	0.84	0.23 - 3.03	7.9E-01	0.48	0.09 - 2.51	3.9E-01	NC	NC	NC
2/3	1.02	0.7 - 1.49	9.1E-01	0.79	0.56 - 1.13	2.0E-01	1.33	0.94 - 1.89	1.1E-01	0.98	0.54 - 1.76	9.4E-01
2/4	2.87	1.72 - 4.81	6.3E-05	2.18	1.38 - 3.45	8.2E-04	0.91	0.57 - 1.45	6.8E-01	1.20	0.56 - 2.57	6.4E-01
3/4	2.73	2.29 - 3.25	2.3E-28	1.72	1.46 - 2.03	8.9E-11	0.67	0.57 - 0.8	4.5E-06	1.28	0.98 - 1.68	6.9E-02
4/4*	5.10	3.83 - 6.8	1.6E-27	1.91	1.51 - 2.41	7.2E-08	0.58	0.45 - 0.75	4.0E-05	0.84	0.54 - 1.31	4.5E-01
Adjusted for age and sex												
2/2*	0.42	0.08 - 2.1	2.9E-01	0.86	0.23 - 3.12	8.1E-01	0.50	0.09 - 2.74	4.3E-01	NC	NC	NC
2/3	1.12	0.76 - 1.63	5.7E-01	0.84	0.59 - 1.21	3.4E-01	1.15	0.8 - 1.65	4.5E-01	0.93	0.51 - 1.67	8.0E-01
2/4	2.65	1.57 - 4.45	2.5E-04	2.11	1.33 - 3.35	1.6E-03	1.09	0.68 - 1.77	7.2E-01	1.27	0.59 - 2.74	5.5E-01
3/4	2.52	2.1 - 3.02	3.6E-23	1.55	1.31 - 1.83	3.8E-07	0.86	0.72 - 1.04	1.2E-01	1.54	1.16 - 2.04	3.1E-03
4/4*	4.33	3.2 - 5.87	1.1E-20	1.56	1.22 - 2.01	4.7E-04	0.93	0.7 - 1.23	6.1E-01	0.96	0.59 - 1.55	8.6E-01
Adjusted for age, sex, and neuropathological diagnosis of AD												
2/2*	0.95	0.16 - 5.55	9.6E-01	1.67	0.43 - 6.49	4.6E-01	0.67	0.12 - 3.71	6.5E-01	NC	NC	NC
2/3	1.49	0.98 - 2.26	6.4E-02	1.02	0.7 - 1.48	9.2E-01	1.23	0.85 - 1.77	2.7E-01	1.08	0.59 - 1.96	8.0E-01
2/4	2.52	1.46 - 4.36	9.5E-04	1.88	1.17 - 3.02	9.4E-03	1.05	0.65 - 1.71	8.3E-01	1.16	0.54 - 2.52	7.0E-01
3/4	2.02	1.67 - 2.45	4.7E-13	1.25	1.05 - 1.49	1.2E-02	0.80	0.66 - 0.96	1.9E-02	1.31	0.99 - 1.75	6.3E-02
4/4	3.34	2.45 - 4.55	5.2E-14	1.20	0.92 - 1.55	1.8E-01	0.86	0.64 - 1.14	2.9E-01	0.83	0.51 - 1.34	4.5E-01

CAA: congophilic amyloid angiopathy; LBD: Lewy body disease; VBI: vascular brain injury; HS: hippocampal sclerosis;

* Confidence in the 2/2 OR estimates is limited by the small number of assessed participants with this genotype. NC: statistical non-convergence.

Since TDP-43 pathology and microinfarcts were not characterized in many of the participants, the impact of APOE genotypes on the presence or absence of those pathological diagnoses were not assessed.

Supplementary Table 7

Other Neuropathological Diagnosis Odds Ratios in Association with APOE2 and APOE4 Allelic Doses,
After Adjustment for Age, Sex, and Neuropathological Diagnosis of AD

	APOE2 Allelic Dose			APOE4 Allelic Dose		
	OR	95% CI	P	OR	95% CI	P
Unadjusted						
CAA	0.93	0.67 - 1.31	6.8E-01	2.43	2.13 - 2.76	1.1E-39
LBD	0.82	0.6 - 1.13	2.2E-01	1.46	1.31 - 1.62	1.4E-11
VBI	1.20	0.87 - 1.65	2.7E-01	0.73	0.65 - 0.83	3.3E-07
HS	0.85	0.49 - 1.48	5.8E-01	1.02	0.85 - 1.23	8.3E-01
Adjusted for age and sex						
CAA	1.00	0.71 - 1.41	9.9E-01	2.26	1.97 - 2.59	1.9E-31
LBD	0.86	0.62 - 1.19	3.6E-01	1.32	1.17 - 1.47	2.6E-06
VBI	1.06	0.76 - 1.48	7.1E-01	0.94	0.82 - 1.06	3.1E-01
HS	0.82	0.47 - 1.42	4.7E-01	1.17	0.96 - 1.43	1.2E-01
Adjusted for age, sex, and neuropathological diagnosis of AD						
CAA	1.36	0.94 - 1.98	1.1E-01	1.90	1.66 - 2.19	2.1E-19
LBD	1.07	0.76 - 1.50	7.1E-01	1.13	1.01 - 1.28	4.1E-02
VBI	1.16	0.83 - 1.62	3.9E-01	0.89	0.78 - 1.02	8.9E-02
HS	0.98	0.55 - 1.73	9.5E-01	1.05	0.86 - 1.29	6.1E-01

CAA: congophilic amyloid angiopathy..LBD: Lewy body disease; VBI: vascular brain injury; HS: hippocampal sclerosis.

ORs associated with APOE2 allelic dose in APOE4 non-carriers (APOE2/2<2/3<3/3) and APOE4 allelic dose in APOE2 non-carriers (APOE4/4>3/4>3/3) were generated using allelic association tests with an additive genetic model.

Since TDP-43 pathology and microinfarcts were not assessed in all participants, the impact of APOE2 and APOE4 allelic doses on the presence or absence of those diagnoses were not assessed

Supplementary Table 8

CERAD (Neuritic A β Plaque) Scores and Braak (Tau Tangle) Stages for Each APOE Genotype, and the Residual Effects of Each Genotype, Compared to APOE3/3, Before and After Adjustment for Age at Death and Sex

APOE	CERAD (Neuritic A β Plaque) Score						Braak (Neurofibrillary Tangle [PHF Tau]) Stage					
	N	Mean \pm SD	Unadjusted		Adjusted for AAD and Sex		N	Mean \pm SD	Unadjusted		Adjusted for AAD and Sex	
			BETA \pm SE	P	BETA \pm SE	P			BETA \pm SE	P	BETA \pm SE	P
2/2	20	1.05 \pm 1.10	-1.04 \pm 0.30	5.6E-04	-1.51 \pm 0.44	6.3E-04	19	2.26 \pm 1.63	-1.65 \pm 0.45	2.7E-04	-1.51 \pm 0.44	6.3E-04
2/3	234	1.33 \pm 1.31	-0.63 \pm 0.09	1.9E-11	-0.78 \pm 0.13	1.3E-09	255	3.16 \pm 1.89	-0.86 \pm 0.13	4.2E-11	-0.78 \pm 0.13	1.3E-09
2/4	1,605	1.93 \pm 1.24	0.42 \pm 0.14	1.9E-03	0.46 \pm 0.17	8.8E-03	1,746	3.94 \pm 1.79	0.57 \pm 0.18	1.4E-03	0.46 \pm 0.17	8.8E-03
3/4	93	2.40 \pm 0.97	0.70 \pm 0.04	4.1E-76	0.84 \pm 0.05	1.5E-53	112	4.57 \pm 1.49	0.93 \pm 0.05	1.7E-65	0.84 \pm 0.05	1.5E-53
4/4	1,632	2.63 \pm 0.78	0.90 \pm 0.06	7.8E-51	1.08 \pm 0.08	5.2E-37	1,831	4.89 \pm 1.30	1.25 \pm 0.08	1.1E-51	1.08 \pm 0.08	5.2E-37


A β : amyloid- β ; PHF: paired helical filament; AAD: Age at Death; SD: standard deviation; SE: standard error; AAD: age at death

BETA \pm SE: estimates and standard errors in a linear regression model from neuropathologically confirmed and misclassified Alzheimer's dementia cases and controls in the entire autopsy group.

CERAD Scores reflect the density of neuritic plaques: 0 (none), 1 (sparse), 2 (moderate), and 3 (frequent); Braak Stages reflect the spatial distribution of neurofibrillary tangles: 0 (none), I-II (transentorhinal and entorhinal cortex), III-IV (hippocampal and neighboring limbic areas), and V-VI (neocortical areas).

Supplementary Figure 1

Impact of APOE2 and APOE4 Allelic Doses on the Classification of Cases and Controls in the Neuropathologically Confirmed Autopsy and Unconfirmed Non-Autopsy Groups




Receiver Operating Characteristic (ROC) curves reflect the impact of APOE2 allelic dose (left) and APOE4 allelic dose (right) on the sensitivity and specificity to classify clinically diagnosed Alzheimer's dementia cases and controls. ROC curves in the neuropathologically confirmed autopsy group are shown in red and those in the neuropathologically unconfirmed non-autopsy group are shown in black.

APOE2 allelic dose reflects the number of APOE2 alleles in APOE4 non-carriers (APOE2/2>2/3>3/3); APOE4 allelic dose reflects the number of APOE4 alleles in APOE2 non-carriers (APOE2/2>2/3>3/3).

As reflected by the Area Under the Curve (AUC), an indicator of classification accuracy, and their 95% confidence intervals, APOE2 and APOE4 allelic doses were each associated with significantly higher AUCs in the neuropathologically confirmed and unconfirmed groups; APOE2 allelic dose was associated with a significantly greater AUC in the neuropathologically confirmed than unconfirmed group, whereas APOE4 allelic dose was not.

Supplementary Figure 2

CERAD (Neuritic A β Plaque) Scores and Braak (Tau Tangle) Stages for Each APOE Genotype in the Neuropathologically Confirmed AD Case-Control Group



The bar graphs show mean and standard error of the mean (SEM) CERAD scores and Braak stages for each APOE genotype and correspond to the mean and standard deviation scores and stages in Supplementary Table 8.